☰

John W. Blankenship, Ph.D. - Publications

Affiliations: 
Scripps Research Institute, La Jolla, La Jolla, CA, United States 
Tree Info Similar researchers PubMed Report error

17 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Comeau MR, Mitchell D, Gottschalk R, Misher L, Daugherty M, Parr L, Pavlik P, Woodruff B, Fang H, Aguilar M, Bannink J, Johnson S, Li G, Miller RE, Bader R, ... ... Blankenship JW, et al. Abstract 597: Bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecules for redirected T-cell cytotoxicity in hematological malignancies Cancer Research. 77: 597-597. DOI: 10.1158/1538-7445.Am2017-597  0.329
2016 Hernandez-Hoyos G, Sewell T, Bader R, Bannink J, Chenault RA, Daugherty M, Dasovich M, Fang H, Gottschalk R, Kumer J, Miller RE, Ravikumar P, Wiens J, Algate PA, Bienvenue D, ... ... Blankenship JW, et al. MOR209/ES414, A Novel Bispecific Antibody Targeting PSMA For The Treatment of Metastatic Castration-Resistant Prostate Cancer. Molecular Cancer Therapeutics. PMID 27406985 DOI: 10.1158/1535-7163.Mct-15-0242  0.32
2016 Blankenship JW, Misher L, Mitchell D, Zhang N, Tan P, Hoyos GH, Ravikumar P, Bader R, McMahan CJ, Miller RE, Bannink J, Fang H, Parr L, Dasovich M, Bienvenue D, et al. Abstract 4995: anti-ROR1 x anti-CD3 ADAPTIR™ molecule, ES425, redirects T-cell cytotoxicity and inhibits tumor growth in preclinical models of triple-negative breast cancer Cancer Research. 76: 4995-4995. DOI: 10.1158/1538-7445.Am2016-4995  0.337
2016 Sewell T, Blake M, Gross JA, Endell J, Weirather J, Blankenship JW. Abstract 280: Synergisticin vitroactivity of MOR209/ES414 in combination with enzalutamide Cancer Research. 76: 280-280. DOI: 10.1158/1538-7445.Am2016-280  0.318
2013 Miller R, Fang H, Luke J, Aguilar M, Chenault R, Kumer J, Wiens J, Algate P, Bienvenue D, McMahan C, Nguyen H, Vessella R, Blankenship J. Abstract 2855: Anti-PSMA x anti-CD3 SCORPIONTMmolecule inhibits tumor growthin vivoin mouse models of prostate cancer. Cancer Research. 73: 2855-2855. DOI: 10.1158/1538-7445.Am2013-2855  0.343
2013 McMahan CJ, Hernandez-Hoyos G, Bannink J, Bader RR, Ravikumar P, Sewell T, Bannink KM, Gottschalk RJ, Fang H, Johnson S, Aguilar M, Kumer J, Algate PA, Bienvenue DL, Blankenship JW. Abstract 1236: Pharmacokinetic evaluation and tolerability assessment of anti-PSMA x anti-CD3 SCORPIONTMmolecule in humanized mice and non-human primates. Cancer Research. 73: 1236-1236. DOI: 10.1158/1538-7445.Am2013-1236  0.345
2013 Hernandez-Hoyos G, Sewell T, Ravikumar P, Aguilar M, Kumer J, Bienvenue D, McMahan CJ, Gross J, Blankenship JW. Abstract B249: Prolonged cytotoxic activity induced by anti-PSMA x anti-CD3 ADAPTIR™ molecule in the absence of significant cytokine release. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-B249  0.348
2012 Chenault RA, Gottschalk R, Hernandez-Hoyos G, Wiens J, Gordon B, Klee J, Bienvenue J, Dasovich M, Kumer J, Aguilar M, Bannink J, McMahan CJ, Natarajan S, Algate PA, Blankenship JW. Bispecific SCORPION™ Molecules Effectively Redirect T-Cell Cytotoxicity Toward CD19-Expressing Tumor Cells Blood. 120: 3722-3722. DOI: 10.1182/Blood.V120.21.3722.3722  0.366
2010 Tong W, Gagnon M, Sprules T, Gilbert M, Chowdhury S, Meerovitch K, Hansford K, Purisima EO, Blankenship JW, Cheung NK, Gehring K, Lubell WD, Saragovi HU. Small-molecule ligands of GD2 ganglioside, designed from NMR studies, exhibit induced-fit binding and bioactivity. Chemistry & Biology. 17: 183-94. PMID 20189108 DOI: 10.1016/J.Chembiol.2010.01.012  0.311
2009 Blankenship JW, Varfolomeev E, Goncharov T, Fedorova AV, Kirkpatrick DS, Izrael-Tomasevic A, Phu L, Arnott D, Aghajan M, Zobel K, Bazan JF, Fairbrother WJ, Deshayes K, Vucic D. Ubiquitin binding modulates IAP antagonist-stimulated proteasomal degradation of c-IAP1 and c-IAP2(1). The Biochemical Journal. 417: 149-60. PMID 18939944 DOI: 10.1042/Bj20081885  0.303
2007 Varfolomeev E, Blankenship JW, Wayson SM, Fedorova AV, Kayagaki N, Garg P, Zobel K, Dynek JN, Elliott LO, Wallweber HJ, Flygare JA, Fairbrother WJ, Deshayes K, Dixit VM, Vucic D. IAP antagonists induce autoubiquitination of c-IAPs, NF-kappaB activation, and TNFalpha-dependent apoptosis. Cell. 131: 669-81. PMID 18022362 DOI: 10.1016/J.Cell.2007.10.030  0.323
2007 Blankenship JW, Dawson PE. Threading a peptide through a peptide: protein loops, rotaxanes, and knots. Protein Science : a Publication of the Protein Society. 16: 1249-56. PMID 17567748 DOI: 10.1110/Ps.062673207  0.501
2005 Bélec L, Blankenship JW, Lubell WD. Examination of structural characteristics of the potent oxytocin antagonists [dPen1,Pen6]-OT and [dPen1,Pen6, 5-tBuPro7]-OT by NMR, Raman, CD spectroscopy and molecular modeling. Journal of Peptide Science : An Official Publication of the European Peptide Society. 11: 365-78. PMID 15641022 DOI: 10.1002/Psc.637  0.318
2003 Blankenship JW, Dawson PE. Thermodynamics of a designed protein catenane. Journal of Molecular Biology. 327: 537-48. PMID 12628256 DOI: 10.1016/S0022-2836(03)00115-3  0.508
2002 Blankenship JW, Balambika R, Dawson PE. Probing backbone hydrogen bonds in the hydrophobic core of GCN4. Biochemistry. 41: 15676-84. PMID 12501196 DOI: 10.1021/Bi026862P  0.474
2001 Hirst J, Wilcox SK, Williams PA, Blankenship J, McRee DE, Goodin DB. Replacement of the axial histidine ligand with imidazole in cytocbrome c peroxidase. 1. Effects on structure Biochemistry. 40: 1265-1273. PMID 11170452 DOI: 10.1021/Bi002089R  0.341
2000 Mäler L, Blankenship J, Rance M, Chazin WJ. Site-site communication in the EF-hand Ca2+-binding protein calbindin D9k. Nature Structural Biology. 7: 245-50. PMID 10700285 DOI: 10.1038/73369  0.31
Show low-probability matches.